Home' Australian Pharmacist : Australian Pharmacist July 2014 Contents Australian Pharmacist July 2014 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
EVIDENCE IN PATIENT CARE
Submit your answers online before
1 September 2014 at www.psa.org.au
and receive automatic feedback, or NZ
members can fax/mail to:
NZCP CPD answers,
PO Box 11 640, Wellington
F: 04 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA’s
CPD & PI program. It is also part of the New
Zealand College of Pharmacists (NZCP) education
program for NZ pharmacists.
The CPD section is recognised under the PSA
CPD & PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions,
4 out of 5 questions, or 3 out of 4 questions
correct is required for the allocation of Group 2
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your
answers online. If you do not have member
access details, you can request them via a
link from the login page.
• Select Pharmacist Members from the blue,
left hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
1. In the management of glabellar
lines with botulinum toxin, how
long does it usually take before the
a) 1 month.
b) 3 months.
c) 6 months.
d) 12 months.
2. Which of the following statements is
a) The effects of botulinum toxin are
b) Botulinum toxin is one of the most toxic
c) Botulinum toxin was first discovered
over 100 years ago.
d) Botulinum toxin is produced by the
anaerobic bacterium Clostridium
3. What proportion of patients
treated for glabellar lines report
at least moderate improvement in
appearance with botulinum toxin?
4. Which of the following adverse
effects are potentially associated
with botulinum toxin injection?
d) All of the above.
5. Contraindications to botulinum toxin
include all of the following, EXCEPT:
a) Myasthenia gravis.
b) Anticoagulant use.
c) Infection at the injection site.
d) Known allergy to botulinum toxin.
14. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind,
randomised, parallel group study to investigate the
dose equivalence of dysport and botox in the treatment
of cervical dystonia. J Neurol Neurosurg Psychiatry
15. Kranz G, Haubenberger D, Voller B, et al. Respective
potencies of botox and dysport in a human skin
model: A randomized, double-blind study. Mov Disord
16. Carruthers JD, Carruthers JA. Treatment of glabellar frown
lines with c. Botulinum-a exotoxin. J Dermatol Surg Oncol
17. Blitzer A, Binder WJ, Aviv JE, et al. The management of
hyperfunctional facial lines with botulinum toxin. A
collaborative study of 210 injection sites in 162 patients.
Arch Otolaryngol Head Neck Surg 1997;123:389–92.
18. Lowe NJ, Maxwell A, Harper H. Botulinum a exotoxin for
glabellar folds: A double-blind, placebo-controlled study
with an electromyographic injection technique. J Am
Acad Dermatol 1996;35:569–72.
19. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter,
double-blind, randomized, placebo-controlled study
of the efficacy and safety of botulinum toxin type a in
the treatment of glabellar lines. J Am Acad Dermatol
20. Rzany B, Dill-Muller D, Grablowitz D, et al. Repeated
botulinum toxin a injections for the treatment of lines in
the upper face: A retrospective study of 4,103 treatments
in 945 patients. Dermatol Surg 2007;33:S18–25 .
21. Finzi E, Wasserman E. Treatment of depression with
botulinum toxin a: A case series. Dermatol Surg
2006;32:645–9; discussion 9–50.
22. Hexsel D, Brum C, Siega C, et al. Evaluation of self-
esteem and depression symptoms in depressed and
nondepressed subjects treated with onabotulinumtoxina
for glabellar lines. Dermatol Surg 2013;39:1088–96 .
23. Neal DT, Chartrand TL. Embodied emotion perception:
Amplifying and dampening facial feedback modulates
emotion perception accuracy. Soc Psych Person Sci
24. Kligman LH, Akin FJ, Kligman AM. Sunscreens promote
repair of ultraviolet radiation-induced dermal damage. J
Invest Dermatol 1983;81:98–102.
25. Kligman LH, Akin FJ, Kligman AM. Prevention of ultraviolet
damage to the dermis of hairless mice by sunscreens. J
Invest Dermatol 1982;78:181–9 .
26. Boyd AS, Naylor M, Cameron GS, et al. The effects of
chronic sunscreen use on the histologic changes of
dermatoheliosis. J Am Acad Dermatol 1995;33:941–6 .
27. Thompson SC, Jolley D, Marks R. Reduction of solar
keratoses by regular sunscreen use. N Engl J Med
28. Green A, Williams G, Neale R, et al. Daily sunscreen
application and betacarotene supplementation in
prevention of basal-cell and squamous-cell carcinomas
of the skin: A randomised controlled trial. Lancet
29. Marks R, Foley PA, Jolley D, et al. The effect of regular
sunscreen use on vitamin d levels in an australian
population. Results of a randomized controlled trial. Arch
30. Marks R. Sunlight and health. Use of sunscreens does
not risk vitamin d deficiency. BMJ 1999;319:1066; author
31. Thibault PK, Wlodarczyk J, Wenck A. A double-blind
randomized clinical trial on the effectiveness of a
daily glycolic acid 5% formulation in the treatment of
photoaging. Dermatol Surg 1998;24:573–7; discussion 7–8 .
32. Stiller MJ, Bartolone J, Stern R, et al. Topical 8% glycolic
acid and 8% l-lactic acid creams for the treatment of
photodamaged skin. A double-blind vehicle-controlled
clinical trial. Arch Dermatol 1996;132:631–6 .
33. Weiss JS, Ellis CN, Headington JT, et al. Topical tretinoin
improves photoaged skin. A double-blind vehicle-
controlled study. JAMA 1988;259:527–32.
34. Griffiths CE, Russman AN, Majmudar G, et al. Restoration
of collagen formation in photodamaged human skin by
tretinoin (retinoic acid). N Engl J Med 1993;329:530–5 .
35. Ipsen Pty Ltd. Dysport approved product information.
36. Allergan Australia Pty Ltd. Botox approved product
information. At: www.Ebs.Tga.Gov.Au/ebs/picmi/
pi-07059-3 . 2013
Links Archive Australian Pharmacist June 2014 Australian Pharmacist August 2014 Navigation Previous Page Next Page